Inventiva S.A. (IVA.PA)
Paris · EUR · Healthcare · Biotechnology
€3.38 (+10.29%) as of
Key statistics
- Market cap
- 797.24M
- Forward P/E
- -5.67
- EPS (TTM)
- -0.5300
- Dividend yield
- 0.00%
- 52-week range
- 2.5700 – 6.2000
- Beta
- 1.00
- Revenue (TTM)
- 2.46M
- Profit margin
- 0.00%
- Analyst target
- €9.77
- Volume
- 1.02M
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Daix, France
- Employees
- 87
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.